Kamada (KMDA) Intangibles (2020 - 2026)
Kamada (KMDA) posted quarterly Intangibles of $95.7 million for Q1 2026, down 5.67% year-on-year from $101.4 million in Q1 2025, and down 1.88% on a QoQ basis from $97.5 million in Q4 2025.
Kamada (KMDA) Intangibles (2020 - 2026) Analysis & Trends
Kamada (KMDA) has reported Intangibles for 7 consecutive years, with $95.7 million the latest figure, recorded in Q1 2026.
- Quarterly Intangibles fell 5.67% year-over-year to $95.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.7 million (down 5.67% YoY) and the FY2025 annual result came in at $97.5 million, down 5.54% from the prior year.
- Intangibles slipped to $95.7 million in Q1 2026 per KMDA's latest filing, from $97.5 million in the prior quarter.
- Over the last five years, Intangibles for KMDA reached as high as $144.0 million in Q2 2023 and fell as low as $145305.0 in Q1 2023.
- A 5-year average of $96.8 million and a median of $103.2 million in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2023 — Intangibles jumped 95782.79% — and 2024, when it dropped 26.51%.
- Year by year, Intangibles stood at $124.7 million in 2022, then gained by 0.1% to $124.8 million in 2023, then decreased by 17.32% to $103.2 million in 2024, then decreased by 5.54% to $97.5 million in 2025, then declined by 1.88% to $95.7 million in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $95.7 million, $97.5 million, and $99.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - | 34.07 Bn |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn | 3.61 Bn |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn | 959.00 Mn |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn | 21.80 Bn |
| 5 | United Therapeutics | 23.05 Bn | 20.90 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | 5.29 Mn |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | 14.48 Bn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | 3.23 Bn |
| 10 | Kamada | 400.07 Mn | 326.92 Mn | 19.12 Mn | 95.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 95.68 Mn |
| Dec 31, 2025 | 97.51 Mn |
| Sep 30, 2025 | 99.19 Mn |
| Jun 30, 2025 | 99.64 Mn |
| Mar 31, 2025 | 101.42 Mn |
| Dec 31, 2024 | 103.23 Mn |
| Sep 30, 2024 | 104.73 Mn |
| Jun 30, 2024 | 106.52 Mn |
| Mar 31, 2024 | 108.31 Mn |
| Dec 31, 2023 | 124.85 Mn |
| Sep 30, 2023 | 142.50 Mn |
| Jun 30, 2023 | 143.99 Mn |
| Mar 31, 2023 | 145,305.00 |
| Dec 31, 2022 | 124.72 Mn |
| Sep 30, 2022 | 148,620.00 |
| Dec 31, 2021 | 154.43 Mn |
| Dec 31, 2020 | 1.49 Mn |